SCHEMBL23999947

SCHEMBL23999947

Cc1cc(Nc2ccc3[nH]c(-c4ccc(Nc5cc(C)nc6ccc(N7CCO[C@H](C)C7)cc56)cn4)nc3c2)ccn1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.41
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMO Q99835 1/20 0.37
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CDK6 Q00534 1/20 0.35
SYK P43405 1/20 0.35
CBFB Q13951 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24003965 1.00 PDPK1 (0.41) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL23999752 1.00 PDPK1 (0.41) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL30180421 1.00 PDPK1 (0.41) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL25826540 0.95 PDPK1 (0.43) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL23999550 0.92 SYK (0.39) MAPTPOLBTSHRMAPK1KMT2A
SCHEMBL30180668 0.92 SYK (0.39) MAPTPOLBTSHRMAPK1KMT2A
SCHEMBL26323193 0.91 MAPT (0.40) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL26323217 0.91 MAPT (0.40) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL24003924 0.91 PDPK1 (0.42) PDPK1MAPTPOLBTSHRMAPK1
SCHEMBL24003925 0.91 PDPK1 (0.42) PDPK1MAPTPOLBTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
CN-115996939-A AKT3 modulators 乔治穆内有限责任公司 2023-04-21 CN disclosed
CN-115867562-A AKT3 modulators 乔治穆内有限责任公司 2023-03-28 CN disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR PDPK1 30/4885MAPT 3962/4885POLB 2552/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR PDPK1 28/4885MAPT 3999/4885POLB 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.